Physiology and Pharmacology of Effects of GLP-1-based Therapies on Gastric, Biliary and Intestinal Motility
Endocrinology · 26.11.2024 · 166 (1)
DOI: 10.1210/endocr/bqae155 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Endocrinology, online erschienen am 21.11.2024. Verfasst von Ryan J Jalleh und 9 weiteren Autor:innen. Beteiligte Einrichtung: Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, SA 5000, Australia. Hauptthemen laut MEDLINE: Glucagon-Like Peptide 1, Gastrointestinal Motility, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 68-mal zitiert (Crossref) und nennt 163 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Glucagon-like peptide-1 (GLP-1) receptor agonists and the dual GLP-1- and glucose-dependent insulinotropic polypeptide receptor co-agonist tirzepatide (referred to here collectively as “GLP-1-based therapy”) are incretin-based therapies being used increasingly in the management of both type 2 diabetes and obesity. They are now recognized to have beneficial effects beyond improved glycemic control and weight loss, including cardiovascular and renal protection. GLP-1-based therapy also slows gastric emptying, which has benefits (lowering postprandial glucose), but also potential risks (eg, hypoglycemia in individuals on insulin or sulphonylurea therapy). Their effects on the gallbladder may also be beneficial, contributing to reducing postprandial triglycerides, but they also potentially increase the risk of biliary disease. In this review, we summarize the effects of GLP-1 and incretin-based therapeutics on gastric, biliary and small intestinal function. An improved understanding of these effects will optimize the use of these drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, SA 5000, Australia.
- Adelaide Medical School, The University of Adelaide, Adelaide, SA 5000, Australia.
- Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Adelaide, SA 5000, Australia.
- Southern Adelaide Diabetes and Endocrine Service, Flinders Medical Centre, Bedford Park, SA 5042, Australia.
- Diabetes, Endocrinology, Metabolism Section, Medical Department I, Katholisches Klinikum Bochum gGmbH, Sankt Josef-Hospital, Ruhr-University, D-44791 Bochum, Germany.
- Intensive Care Unit, Royal Adelaide Hospital, Adelaide, SA 5000, Australia.
ORCID-Profile: Ryan J Jalleh, Christopher K Rayner, Karen L Jones, Michael A Nauck, Michael Horowitz
Zitieren
APA
Jalleh, R. J., Marathe, C. S., Rayner, C. K., Jones, K. L., Umapathysivam, M. M., Wu, T., Quast, D. R., Plummer, M. P., Nauck, M. A., & Horowitz, M. (2024). Physiology and Pharmacology of Effects of GLP-1-based Therapies on Gastric, Biliary and Intestinal Motility. Endocrinology, 166(1). https://doi.org/10.1210/endocr/bqae155
Vancouver
Jalleh RJ, Marathe CS, Rayner CK, Jones KL, Umapathysivam MM, Wu T, et al. Physiology and Pharmacology of Effects of GLP-1-based Therapies on Gastric, Biliary and Intestinal Motility. Endocrinology. 2024;166(1). doi:10.1210/endocr/bqae155
BibTeX
@article{Jalleh2024,
author = {Jalleh, Ryan J and Marathe, Chinmay S and Rayner, Christopher K and Jones, Karen L and Umapathysivam, Mahesh M and Wu, Tongzhi and Quast, Daniel R and Plummer, Mark P and Nauck, Michael A and Horowitz, Michael},
title = {Physiology and Pharmacology of Effects of GLP-1-based Therapies on Gastric, Biliary and Intestinal Motility},
journal = {Endocrinology},
year = {2024},
volume = {166},
number = {1},
doi = {10.1210/endocr/bqae155}
}
EUVIMED